A double-blind, randomized Phase II study to determine efficacy and safety of oral treatment with BIBF 1120 ES 250 mg twice daily versus 150 mg twice daily in patients suffering from advanced non-small-cell lung cancer.

Trial Profile

A double-blind, randomized Phase II study to determine efficacy and safety of oral treatment with BIBF 1120 ES 250 mg twice daily versus 150 mg twice daily in patients suffering from advanced non-small-cell lung cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2014

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 12 Oct 2009 Pharmacokinetic outcomes presented at the 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology.
    • 01 Sep 2009 Pharmacokinetic outcomes have been reported at the 13th World Conference on Lung Cancer.
    • 03 Aug 2009 Pharmacokinetic results presented at 13th WCLC.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top